Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

16 April 2018

Financing led by GV to focus on lead programs for next-generation oncology cell therapies Proprietary platform enables installation of pharmacologic operating systems in cell and gene therapy products to provide treating physicians with precise and dynamic control of engineered cells in patients December 06, 2017 06:15 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Obsidian Therapeutics, Inc., […]

Continue Reading